ALIOPHTHA AG has a total of 59 patent applications. Its first patent ever was published in 2012. It filed its patents most often in WIPO (World Intellectual Property Organization), Argentina and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals and biotechnology are ARTYMIUK PETER, YITAI MEDICINE RES SHENZHEN CO and DEBIOVISION INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 6 | |
#2 | Argentina | 5 | |
#3 | EPO (European Patent Office) | 5 | |
#4 | Taiwan | 5 | |
#5 | United States | 5 | |
#6 | Australia | 3 | |
#7 | Brazil | 3 | |
#8 | Canada | 3 | |
#9 | China | 3 | |
#10 | Republic of Korea | 3 | |
#11 | Morocco | 3 | |
#12 | Singapore | 3 | |
#13 | Tunisia | 3 | |
#14 | Mexico | 2 | |
#15 | Philippines | 2 | |
#16 | Chile | 1 | |
#17 | Colombia | 1 | |
#18 | Israel | 1 | |
#19 | India | 1 | |
#20 | South Africa | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Peptides | |
#2 | Therapeutic chemical compounds | |
#3 | Medical preparations | |
#4 | Microorganisms |
# | Name | Total Patents |
---|---|---|
#1 | Flammer Josef | 48 |
#2 | Neutzner Albert | 48 |
#3 | Huxley Alice | 48 |
#4 | Josef Flammer | 5 |
#5 | Alice Huxley | 5 |
#6 | Albert Neutzner | 5 |
Publication | Filing date | Title |
---|---|---|
TW201736394A | Endosomal disentanglement of artificial transcription factors | |
WO2016050934A1 | Endosomal disentanglement of artificial transcription factors | |
TW201514202A | Artificial transcription factors engineered to overcome endosomal entrapment | |
TW201514200A | Artificial transcription factors for the treatment of diseases caused by OPA1 haploinsufficiency | |
TW201441249A | Artificial transcription factors and their use for the treatment of maladapted wound healing in the eye | |
TW201514201A | Artificial transcription factors regulating nuclear receptors and their therapeutic use | |
US2014296129A1 | Regulation of receptor expression through delivery of artificial transcription factors |